AbsTRACT INTRODUCTION Epidemio logic data show a higher frequency of thromboembolic incidents in obese individuals compared with normal weight subjects. Pro-inflammatory factors seem to play an important role in their development. It has not been fully explained so far how α 1 -antitrypsin (α 1 ATp) and α 2 -macroglobulin (α 2 MG) act in obese subjects. Both proteins participate directly and indirectly in regulation of inflammation, coagulation and fibrinolysis. Thus alterations in serum levels of these protease inhibitors may play an important role in the development of vascular incidents in obesity.
INTRODUCTION A markedly higher incidence of vascular thromboembolic episodes in the obese patients as compared to the normal weight sub jects has been observed in a number of epidemio logical studies. These incidents affect both venous and arterial systems and are the main causes of death in obese patients. Metabolic distur bances occurring in obesity seem to play a ma jor role in the development of thromboembo lic episodes. It is well known that hyperglyce mia, insulin resistance with secondary hyperinsu linemia or arterial hypertension adversely affect hemo stasis at several levels.
1-5 Numerous reports have confirmed an increase in coagulation factors (VIII, IX, XI, von Willebrand) and an increased plasminogen activator inhibitor type 1 activity in obese patients.
6-15 Growing attention is being paid to the inflammatory etiology of the devel opment of vascular lesions. Recent reports have confirmed the contribution of proinflammato ry factors to the development of atherosclero sis. [16] [17] [18] Available data provide numerous reports evaluating levels of acutephase proteins, i.e. Cre active protein (CRP), proinflammatory cytok ines or fibrinogen in obese subjects. 19, 20 There are several ambiguities concerning the action of en dogenous inhibitors of proteases, which belong to acutephase proteins, including α1antitrypsin (α1ATp) or α2macroglobulin (α2MG), in the de velopment of vascular complications. A particular INTRODUCTION Epidemio logic data show a higher frequency of thromboembolic incidents in obese individuals compared with normal weight subjects. Pro-inflammatory factors seem to play an important role in their development. It has not been fully explained so far how α 1 -antitrypsin (α 1 ATp) and α 2 -macroglobulin (α 2 MG) act in obese subjects. Both proteins participate directly and indirectly in regulation of inflammation, coagulation and fibrinolysis. Thus alterations in serum levels of these protease inhibitors may play an important role in the development of vascular incidents in obesity.
ObjECTIvEs To assess serum α 1 ATp and α 2 MG levels in obese patients. PATIENTs AND mEThODs The study involved 16 subjects with obesity and meta bolic syndrome and 14 obese subjects with no disturbances of glucose and lipid profile or arterial hypertension. 20 healthy volunteers served as the control group. Levels of α 1 ATp and α 2 MG were determined in all subjects using immunonephelometry.
REsULTs No significant differences in α 1 ATp and α 2 MG levels between the patients and the control group were observed. Comparison of the tested para meters in the obese with meta bolic syndrome and those without meta bolic disturbances showed higher values of α 1 ATp levels in the former group. In this group positive correlations between α 1 ATp levels and fasting insulin levels were found.
CONCLUsIONs Metabolic disturbances in obesity are associated with an elevated level of α 1 ATp, which might confirm its important role in the development of vascular incidents in obese patients. An increased risk of vascular patho logical lesions in obesity is probably not associated with α 2 MG levels.
KEy wORDs
α 1 -antitrypsin, α 2 -macroglobulin, meta bolic syndrome, obesity PATIENTs AND mEThODs 30 patients (20 wom en and 10 men, mean age 38.2 ±14.3 years) with obesity (BMI ≥30 kg/m 2 ) admitted to the De partment of Endocrinology and Internal Med icine, Medical Academy, Gdańsk, were enrolled in the study, in order to perform hormonal eval uation. Patients with acute or chronic infection, cancer, systemic connective tissue disease, liver damage, women on contraceptives or on hormone replacement therapy and patients with a histo ry of a thromboembolic episode over a period of 6 months were excluded from the study based on the thorough subjective and objective exam ination, and on the results of laboratory tests. There were 4 patients with hypercortisolemia, 3 patients with symptoms of hyperandrogenism and 1 patient with the poststeroidal adrenal fail ure in the analyzed group. 16 patients met the cri teria for meta bolic syndrome, whereas 14 patients did not show either disturbances in carbohydrate and lipid meta bolism or arterial hypertension. The control group consisted of 20 healthy vol unteers (health care workers, members of their family) with a normal weight matched for their gender and age. A subjective and objective exami nation, including basic anthropometric evaluation, was performed in all participants of the study.
Blood for the laboratory tests was drawn from the basilic vein, following at least the 30min ute rest at supine position, in a fasting state, in the morning. The serum obtained by spinning down the blood samples was divided into 2 por tions and stored in sterile plastic tubes at −70ºC, and then transferred into room temperature just prior to the determination of the individual para meters.
Levels of α1ATp and α2MG were determined in all individuals. The tests were performed in the Central Clinical Laboratory of Academ ic Clinical Centre, Medical Academy, Gdańsk. The levels of α1ATp and α2MG were tested us ing immunonefelometry and the following re agents, N Antisera α1 Antitrypsin and α2 Mac roglobulin (DadeBehring, Germany), according to the manufacturer's instructions. Intra and inter assay variability were as follows: for α1ATp 2.0, 3.2% and for α2MG 1.6, 3.0%, respectively. Parameters of the coagulation system (activated partial thromboplastin time, inter national nor malized ratio, fibrinogen level, antithrombin and protein C activity), lipid profile and carbohydrate meta bolism para meters, i.e. glycemia and fasting role in these events plays α1ATp, as, apart from its contribution to the inflammatory process, it also seems to affect hemo stasis. It is well known that it indirectly increases the activity of coagula tion factors, i.e. II, V, VIII, XII and XIII and inhib its activated protein C, which represents the en dogenous anticoagulant system. 21, 22 The impact of α2MG on hemo stasis activity is also significant. Similarly to α1ATp, it inhibits activated protein C and affects the inactivation of prothrombin and plasminogen activators. 23 Therefore, changes in the activity and levels of both serine protease inhibitors may indirectly influence the development of vascular complica tions obesity. Thus it seems that the assessment of the particular para meters in this group of pa tients is fully justified.
The aim of the present study was to determine serum α1ATp and α2MG levels in obese patients (body mass index [BMI] ≥30 kg/m 2 ). In the recent years, more and more at tention has been paid to the influence of proin flammatory cytokines on the hemo stasis sys tem and the development of vascular complica tions in obese patients. 19, 20 There are few papers on obese individuals evaluating levels of α1ATp and α2MG, which are the endogenous serine pro tease inhibitors. In the present study no differ ences in tested para meters between the group of obese patients and controls were observed. However, the study demonstrated a significantly higher level of α1ATp in patients with meta bolic syndrome than in obese normotensive individ uals without disturbances in meta bolism of car bohydrates and lipids. Patients from the latter group, described in available data as "metaboli cally healthy but obese", present a normal meta bolic profile despite the obesity. 24 The comparison of the results obtained during the current study with those provided by available data is difficult as most authors have evaluated in their stud ies a group of 5 proteins associated with the in flammation (inflammationsensitive plasma pro teins -ISPs), i.e. ceruloplasmin, α1ATp, hapto globin, fibrinogen and plasma acidic glycopro tein -orosomucoid, without taking into account the roles of particular proteins in their analy ses. It has been consistently reported that in creased levels of ISPs are linked to an increased risk of vascular complications. [25] [26] [27] [28] [29] More data on the action of particular protease inhibitors was provided by the study by Karelis et al., who found significantly higher levels of inflamma tionsensitive plasma proteins, like, for instance, α1ATp, in obese postmenopausal women with in sulin resistance and dyslipidemia as compared to women without meta bolic disturbances.
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At the same time, Engstrom reported a negative correlation between the level of α1ATp and BMI in men with classic cardiovascular risk factors.
25
In the current study there was no significant cor relation between the α1ATp level and BMI. How ever, the study showed a significant positive cor relation between the α1ATp level and the fasting level of insulin. Therefore, increased α1ATp lev els do not seem to depend directly on the degree of obesity, but on the coexisting meta bolic dis orders. These results are confirmed by Faraj et al., insulin levels, occasional glycemia, glucose toler ance test (in patients whose glucose levels were in the range of 100 to 125 mg/dl) were measured in obese patients using standard methods.
The Ethics Committee approved the study. Par ticipants gave their written consent.
In the analysis of the variables the meth ods of statistical conclusion with the use of the STATISTICA computer program were applied. The mean values and standard deviations were cal culated. The SaphiroWilk test was used to eval uate the distribution of variables. To compare the differences between the groups, the variables were further analyzed using the nonparametric MannWhitney U test and Spearman's test eval uating the correlations between the variables. A p <0.05 was considered significant.
REsULTs
The characteristics of the study group have been shown in TAbLE 1.
The comparison of α1ATp and α2MG levels in obese and normal individuals did not show any statistically significant differences between both groups (TAbLE 2) . However, analysis of the mea sured para meters in subgroups, with regard to the meta bolic disturbances present, showed significantly higher α1ATp levels in patients ful filling the criteria for meta bolic syndrome as com pared to the obese patients without concomitant meta bolic disturbances. There was no such corre lation for α2MG. (TAbLE 3) .
The analysis of para meters showed no sta tistically significant differences in the groups of the same gender (TAbLE 4). In the subgroups formed with regard to the meta bolic disturbanc es within a group of the same gender statistical analysis was not performed as the number of pa tients was too small. Next, the relationship between the para meters determined and the BMI and waist to hip ratio in dex was analyzed, and no significant correlation among the studied para meters was found.
The results obtained were further analyzed in relation to the coexisting meta bolic distur bances. In patients with meta bolic syndrome, a statistically significant correlation between the level of α1ATp and the fasting level of insu lin was observed. No statistically significant rela tionship was found between the levels of α1ATp and α2MG and lipid para meters.
DIsCUssION Available data provide numer ous reports on the factors increasing the risk of of vascular complications in these patients. However, α2MG is probably not responsible for the high risk of vascular lesions in obesity.
who showed a significant correlation between α1ATp levels and the HOMA index in obese post menopausal patients. 31 In turn, Cymerys et al. did not find significantly higher levels of this para meter in patients with arterial hypertension.
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Over recent years, growing emphasis has been placed on the role of proinflammatory factors in atherogenesis in meta bolic disorders. Sever al lines of evidence have demonstrated an in crease in CRP, fibrinogen or proinflammatory cytokine levels in patients with hyperglycemia, in sulin resistance or dyslipidemia. 33, 34 It is impor tant to stress that α1ATp also belongs to a fam ily of acutephase proteins. Its increased levels seem to confirm a significant role of an inflam matory process in the development of vascular le sions in patients with meta bolic syndrome. The ef fect of α1ATp on hemo stasis is also significant. It abolishes elastase action on particular para meters of coagulation and the fibrinolysis due to its inac tivation, including a decrease in coagulation fac tors II, V, VIII, XII, XIII activity and profibrinolyt ic effect. 21 α1ATp directly inhibits CRP, an endog enous anticoagulant, and the levels of complex es of active protein C and α1ATp may serve as a marker of high risk of thrombosis. 21, 35 There fore α1ATp, either directly, by elastase inactiva tion, or indirectly, by stimulation of thrombin generation and inhibition of fibrinolysis, leads to enhanced blood clotting.
A definitely fewer number of papers relates to the profile of α2MG levels in a group of obese patients. Relevant data are controversial. The au thors of recent reports have obtained conflict ing results. Bogdański et al. showed significant ly higher α2MG levels in patients with meta bolic syndrome than in controls. They did not find any significant correlation between levels of the pro tein tested and BMI or the waist circumference.
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On the other hand, Rugsarash et al. showed sig nificantly lower α2MG levels in obese Thais, with out evaluation of concomitant meta bolic distur bances. 37 The current study did not find signif icant differences in levels of the protein tested between the group of the obese patients and the controls, regardless of whether they were accompanied with meta bolic disorders or not. However, it should be noted that obese patients are not a uniform group; they present with vari ous coexisting disturbances of not only a meta bolic nature but also of endocrine origin, which may affect the changes in α2MG levels to a dif ferent degree and with varying dynamics. Eluci dation of these issues obviously requires further studies on larger groups of patients.
The results of the current study do not answer all the questions, but they refer to a very impor tant problem regarding the action of selected in hibitors of serine proteases in obese patients.
The findings of the studies performed and avail able data suggest that increased levels of α1ATp are associated with the incidence of meta bolic dis turbances in obese subjects, which may indirect ly indicate its contribution to the development
